Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors addresses brain anatomy and tumors and the progress and challenges in delivering drugs across the blood brain barrier. Several chapters are devoted to the latest technologies and advances in nanotechnology, along with practical solutions on how to design more effective nanocarriers for drug and gene delivery. This valuable resource prepares readers to develop novel drug delivery systems for the treatment of brain tumors that further promote the latest nanomedical technologies. Addresses the progress and challenges inherent in delivering drugs across the blood brain barrier and offers strategies to maximize effectiveness Draws upon the experience and expertise of international scientists working in the fields of drug delivery and nanomedicine Considers the future possibilities of nanotechnology for delivering nanocarriers that better diagnose and treat brain tumors
Brain Targeted Drug Delivery Systems: A Focus on Nanotechnology and Nanoparticulates provides a guide on nanoparticulates to both academic and industry researchers. The book discusses key points in the development of brain targeted drug delivery, summarizes available strategies, and considers the main problems and pitfalls evidenced in current studies on brain targeted drug delivery systems. As the brain is the most important organ in the human body, and disorders of the central nervous system (CNS) are the most serious threat to human life, this book highlights advances and new research in drug delivery methods to the brain. Provides an overview of brain targeting drug delivery that is useful to both academic and industry-based researchers Discusses key points in developing brain targeting drug delivery systems Summarizes and presents currently available strategies for brain targeting drug delivery Covers not only current studies and their strengths, but also gives insight into the pitfalls of current research
Nano Drug Delivery Strategies for the Treatment of Cancers discusses several current and promising approaches for the diagnosis and treatment of cancer by using the most recent developments in nanomedical technologies. The book presents introductory information about the biology of different types of cancer in order to provide the reader with knowledge on their specificities. In addition, it discusses various novel drug delivery systems, detailing their functionalities, expected outcomes and future developments in the field, focusing on brain, mouth and throat, breast, lung, liver, pancreas, stomach, colon, bool, skin and prostate cancers. The book is a valuable source for cancer researchers, oncologists, pharmacologists and nanotechnologists who are interested in novel drug delivery systems and devices for treatment of various types of cancer that take advantage of recent advances in this exciting field. Discusses a wide range of promising approaches for the diagnosis and treatment of cancer using the latest advancement in cutting-edge nanomedical technologies Provides foundational information on different types of cancer and their biology to help the reader choose the best nano drug delivery system for patients Presents novel drug delivery systems based on nanoparticles, microparticles, liposomes, self-assembling Micelles and block copolymer micelles
Nanocarriers for Drug-Targeting Brain Tumors covers different types of nanocarriers and their design and development for targeting drugs to the brain. The book also presents case studies and the mechanism of action of nanocarriers in drug targeting to a specific site. This helps researchers and clinicians understand the design, development and mechanism of action of nanocarriers. As brain tumors continue to be a significant health problem globally, and very complex for targeting drugs, conventional dosage forms are not very effective and side-effects are a major concern. Functionalized nanocarriers can address these problems. Furthermore, the targeting of nanocarriers is preferred for reducing toxicity and improving the effectiveness of the drugs. However, there is a need for understanding the design and development of formulation with the mechanism of action of nanocarriers for brain targeting. Provides information on the design and development of nanocarriers for targeting brain tumors Outlines the working principles of different nanocarriers for targeting brain tumors Includes case studies of different nanocarriers for targeting brain tumors
This new volume, Nanocarriers for Brain Targeting: Principles and Applications, covers recent research on brain physiology and the development of drug delivery systems. It explores a diverse variety of strategies that can be employed to achieve drug targeting to the brain. The nanocarriers that are discussed include nanoparticles, vesicular carriers, carriers having carbon as a core constituent, dispersed systems, and more. The inherent anatomy and physiology of the brain renders it different from other organs. The past few decades have witnessed significant research on brain ailments in response to a majority of hospitalizations that occur due to age-related central nervous system disorders. The prevalence of diverse diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, HIV-dementia, etc., affect about 1.5 billion people globally, which is further anticipated to reach 1.9 billion by the year 2020. Nanocarriers for drug delivery to the brain are seen as one of the answers to this growing problem.
Nanotechnology Methods for Neurological Diseases and Brain Tumors: Drug Delivery across the Blood-Brain Barrier compiles the latest (and future potential) treatment strategies for brain tumors and neurological diseases, in particular Alzheimer’s, Parkinson’s and stroke, those that bypass the blood/brain barrier. The current understanding of brain drug delivery and access is discussed in Chapter One, with the next section focusing on the implementation of the nose-to-brain intranasal route in brain-targeted drug delivery. In addition, nanotechnology-based brain drug delivery is covered in Chapter Three. This avenue offers impressive improvement in the treatment of neurological diseases and brain tumors by using bio-engineered systems that interact with biological systems at a molecular level. In Chapter Four, emphasis is placed on the need for brain-targeted experimental models that mimic disease conditions. Final chapters discuss the very latest advances in targeted treatment strategies for neurological diseases and brain tumors. Comprehensive guide for up-to-date views on the latest advances in targeted treatment strategies for brain tumors and neurological diseases Designed with a multidisciplinary approach that links neurology, neuro-oncology and nanoscience to drug delivery to the brain with an emphasis on the blood-brain-barrier Written in a language that makes it easy to understand nanotechnology drug delivery techniques Presents a unique book that also covers advanced treatment approaches of neurological diseases and brain tumors
Brain tumors refer to a heterogeneous group of primary and metastatic neoplasms in the central nervous system and are one of the life-threatening diseases which are characterized by low survival rate (1). According to GLOBOCAN 2018, nearly 296,851 new cases of brain and nervous system tumors and 241037 deaths are diagnosed in 2018 worldwide. In India 28142 new brain tumor cases annually are reported while deaths were 24003 in 2018 (2). The estimated incidence, mortality and 5 year prevalence of brain tumor among men in India is approximately 11855, 9574 and 17251 respectively which represents 2.5%, 2.7% and 2.6% of Indian population respectively while for women it is 6976 (1.3%), 5578 (1.7%) and 10157 (1%) respectively. More than 120 types of brain tumors are identified till date and depending on the origin of tumor, most common tumors are grouped as tumors of neuroepithelial tissue, tumors of cranial and spinal nerve, tumors of meninges, heamopoitic origin neoplasm and lymphomas, tumor of sellar region, germ cell tumors and cysts (3,4). The most prevalent brain tumors are intracranial metastases from systemic cancers, meningiomas, and gliomas, specifically, glioblastoma (1,5). Glioma is the most frequent primary brain cancer which accounts for 29% of all primary brain and CNS tumors and 80% of alignant brain tumors. These malignant gliomas are primary tumors that are derived from glial origin and account for approximately 70% of new primary brain cancer diagnosis. The classification, grading, and treatment of this diverse group of tumors have been primarily based on morphological criteria, which introduced a certain degree of interpretative subjectivity and moreover provided only suboptimal accuracy for the prediction of treatment response (6). WHO has classified glioma in three category viz. astrocytoma, oligodendrogliomas and mixed gliomas (oligoastrocyotomas). Amongst gliomas, glioblastomamultiforme (GBM) which is a grade IV astrocytoma according to the World Health Organization (WHO) classification, is the most common and aggressive form of glioma in nature (3,6). The median survival for glioblastoma is 14 months (7). The high mortality rate due to GBM can be attributed to specific properties of glioma which includes highly infiltrative nature and lack of clear margin. The existing therapy for GBM is nonspecific and almost fails to prevent reoccurrence of disease.
Nanotechnology has the potential to change every part of our lives. Today, nanotechnology-based products are used in many areas, and one of the most important areas is drug delivery. Nanoparticulate drug delivery systems not only provide controlled delivery of drugs and improved drug solubility but also improve drug efficiency and reduce side effects via targeting mechanisms. However, compared with conventional drug delivery systems, few nanoparticle-based products are on the market and almost all are nontargeted or only passively targeted systems. In addition, obtaining targeted nanoparticle systems is quite complex and requires several evaluation mechanisms. This book discusses the production, characterization, regulation, and currently marketed targeted nanoparticle systems in a broad framework. It provides an overview of targeted nanoparticles’ (i) in vitro characterization, such as particle size, stability, ligand density, and type; (ii) in vivo behavior for different targeting areas, such as tumor, brain, and vagina; and (iii) current advances in this field, including clinical trials and regulation processes.
This authoritative volume explores the fundamental concepts and numerous applications of targeted delivery of drugs to the body. This compilation has been divided into eight sections comprised of the basic principles of drug targeting, disease and organ/organelle-based targeting, passive and active targeting strategies, and various advanced drug delivery tools such as functionalized lipidic, polymeric and inorganic nanocarriers. Together, the twenty-three chapters cover a wide range of topics in the field, including tumor and hepatic targeting, polymer-drug conjugates, nanoemulsion, physical and biophysical characteristics of nanoparticles, and in vivo imaging techniques, among others. The book also examines advanced characterization techniques, regulatory hurdles and toxicity-related issues that are key features for successful commercialization of targeted drug delivery system products. Targeted Drug Delivery is a comprehensive reference guide for drug delivery researchers, both beginners and those already working in the field.
Despite progress in surgery, radiotherapy, and chemotherapy, an effective treatment of gliomas does not yet exist. This new monograph in the ASME-Momentum Press series on Biomedical & Nanomedical Technologies book shows how nanotechnology could be used both to improve the treatment efficacy and to reduce the adverse side effects. It will explain how nanotechnology-based approaches to targeted delivery of drugs across the brain-blood barrier may potentially be engineered to carry out specific functions as needed.
In recent years, nanoparticles—bionanomaterials with specific physicochemical properties—have gained a great deal of scientific interest owing to their unique structure. Nanoparticle-based drugs are now widely regarded as a safer, more precise, and more effective mode of cancer therapy, considering their ability to enhance drug bioavailability, improve site-specific drug delivery, and protect nontarget tissues from toxic therapeutic drugs. This book compiles and details cutting-edge research in nanomedicine from an interdisciplinary team of international cancer researchers who are currently revolutionizing drug delivery techniques through the development of nanomedicines and nanotheranostics. Edited by Hala Gali-Muhtasib and Racha Chouaib, two prominent cancer researchers, this book will appeal to anyone involved in nanotechnology, cancer therapy, or drug delivery research.
Nanotechnology-based Targeted Drug Delivery Systems for Lung Cancer is an indispensable resource that will help pharmaceutical scientists and clinical researchers design and develop novel drug delivery systems and devices for the treatment of lung cancer. As recent breakthroughs in nanomedicine are now making it possible to deliver drugs, genes and therapeutic agents to localized areas of disease to maximize clinical benefit, while also limiting unwanted side effects, this book explores promising approaches for the diagnosis and treatment of lung cancer using cutting-edge nanomedical technologies. Topics discussed include polymeric nanoparticles, solid lipid nanoparticles, liposomes, dendrimers, micelles and nanoemulsions. Provides an overview of an array of nanotechnology-based drug delivery systems Examines the design, synthesis and application of different nanocarriers in drug and gene delivery Provides an in-depth understanding of the design of targeted nanotherapeutics and technologies and its implication in various site-specific cancers
